Takeda and Pronova enter TAK-085 into final testing phases

Takeda, along with its partner Pronova BioPharma ASA, has revealed that its hypertriglyceridemia treatment TAK-085 has been submitted for the final stages of clinical testing.

The two firms entered into an agreement to license and supply the therapy, which is a highly concentrated preparation of the ethyl esters of omega-3 fatty acids.

It is already available in several countries as an adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapies such as statins, antiplatelet drugs, betablockers and ACE inhibitors.

“We are glad that the development of TAK-085 has been successful and phase III clinical programmes can be started so that we may be able to provide it to patients as a new treatment option for hypertriglyceridemia,” stated Nancy Joseph-Ridge, general manager of the pharmaceutical development division of Takeda.

In other Takeda news, last month the firm revealed that it has submitted an application for further indications for its Takepron Capsules 15 and Takepron OD Tablet 15 (lansoprazole).